Research map: Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage

Back to the article

Papers in this map

  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes · Bernard Zinman · 2015 · 12293 citations · Cited by this paper
  2. Associations of cumulative exposure and dynamic trajectories of the cholesterol–HDL–glucose index and its obesity-related derivatives with cardiovascular disease: a nationwide prospective cohort study · 2026 · Related
  3. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes · Bruce Charles Neal · 2017 · 7911 citations · Cited by this paper
  4. Deep learning analysis of ECGs detects Cardiovascular–Kidney–Metabolic syndrome burden in people with diabetes: a report from the Silesia Diabetes-Heart Project · 2026 · Related
  5. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction · John J.V. McMurray · 2019 · 7146 citations · Cited by this paper
  6. Predicting all-cause and cardiovascular mortality in hypertensive patients by combining the CHG index and its obesity indicators: a prospective cohort study with survival prediction model · 2026 · Related
  7. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes · Stephen D. Wiviott · 2018 · 6475 citations · Cited by this paper
  8. Divergent mitochondrial and fibrotic signatures in atrial fibrillation: insights from organoids and GEO data · 2026 · Related
  9. Dapagliflozin in Patients with Chronic Kidney Disease · Hiddo J.L. Heerspink · 2020 · 5532 citations · Cited by this paper
  10. STIM1-mediated Treg instability in HFpEF: a new immunological target emerges? · 2026 · Related
  11. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure · Milton Packer · 2020 · 5221 citations · Cited by this paper
  12. Joint longitudinal trajectories of the triglyceride-glucose index combined with BMI and waist-to-height ratio and incident cardiovascular disease: a prospective cohort study from the English longitudinal study of ageing · 2026 · Related
  13. Identifying Small Molecules via High Resolution Mass Spectrometry: Communicating Confidence · Emma Schymanski · 2014 · 4548 citations · Cited by this paper
  14. Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study · 2026 · Related
  15. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes · Christoph Wanner · 2016 · 3687 citations · Cited by this paper
  16. Predictive significance of triglyceride-glucose index in forecasting adverse cardiovascular events among Type 2 diabetes mellitus patients with co-existing metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from two cohort studies · 2026 · Related
  17. HMDB 5.0: the Human Metabolome Database for 2022 · David Scott Wishart · 2021 · 2669 citations · Cited by this paper
  18. Baseline, repeated-measure burden, and two-time-point patterns of the triglyceride-glucose index-visceral lipid ratio (TyG-VLR) and incident cardiovascular disease in cardiovascular-kidney-metabolic (CKM) syndrome stages 0–3: a longitudinal China Health and Retirement Longitudinal Study (CHARLS) analysis · 2026 · Related
  19. Empagliflozin in Patients with Chronic Kidney Disease · The EMPA-KIDNEY Collaborative Group · 2022 · 2647 citations · Cited by this paper
  20. Direct Cardiac Mechanisms of the Sodium Glucose Co-Transporter 2 Inhibitor Class · 2025 · Related
  21. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial · Ofri Mosenzon · 2019 · 686 citations · Cited by this paper
  22. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition · Volker Vallon · 2016 · 636 citations · Cited by this paper
  23. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function · Volker Vallon · 2020 · 514 citations · Cited by this paper
  24. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus · Daniel S. Hsia · 2016 · 511 citations · Cited by this paper
  25. Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus · Kristina Striepe · 2017 · 180 citations · Cited by this paper
  26. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects · Jason R.B. Dyck · 2022 · 177 citations · Cited by this paper
  27. Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease · Ben Arpad Kappel · 2017 · 158 citations · Cited by this paper
  28. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation · Christian Ott · 2017 · 149 citations · Cited by this paper
  29. Metabolic Communication by SGLT2 Inhibition · Anja M. Billing · 2023 · 149 citations · Cited by this paper
  30. Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms · Keming Huang · 2023 · 119 citations · Cited by this paper
  31. Empagliflozin Inhibits Na+/H+ Exchanger Activity in Human Atrial Cardiomyocytes · Maximilian Trum · 2020 · 115 citations · Cited by this paper
  32. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF · Senthil Selvaraj · 2022 · 103 citations · Cited by this paper
  33. Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2 · Qingqing Wu · 2023 · 89 citations · Cited by this paper
  34. NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation · Jing Shi · 2023 · 86 citations · Cited by this paper
  35. Central Pulse Pressure Is an Independent Determinant of Vascular Remodeling in the Retinal Circulation · Christian Ott · 2013 · 71 citations · Cited by this paper
  36. New software analyses increase the reliability of measurements of retinal arterioles morphology by scanning laser Doppler flowmetry in humans · Joanna Maria Harazny · 2011 · 66 citations · Cited by this paper
  37. NAT10 promotes vascular remodelling via mRNA ac4C acetylation · Cheng Yu · 2024 · 56 citations · Cited by this paper
  38. SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice · Justin H. Berger · 2024 · 36 citations · Cited by this paper
  39. Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction · Hongxia Ma · 2024 · 35 citations · Cited by this paper

Source: OpenAlex (CC0)